Abstract: The disclosure provides compounds of formula (II) having the structure: Compounds of formula (II) are fractalkine receptor agonists and useful in treating, preventing or minimizing metastasis in a subject diagnosed with cancer. The compounds of the disclosure are further useful in treating central nervous system diseases (such as, but not limited to, HIV Associated Neurocognitive Disorders (HAND), and/or Alzheimer's disease), pain, inflammation (such as, but not limited to, arthritis), cardiovascular disease (such as, but not limited to, undesired vascular smooth muscle proliferation, atherosclerosis, coronary vascular endothelial dysfunction, and/or coronary artery disease), and/or multiple sclerosis.

Abstract: The invention provides compounds that are fractalkine receptor agonists and useful in treating, preventing or minimizing metastasis in a subject diagnosed with cancer. The compounds of the invention are further useful in treating central nervous system diseases (such as, but not limited to, HIV Associated Neurocognitive Disorders (HAND), and/or Alzheimer's disease), pain, inflammation (such as, but not limited to, arthritis), cardiovascular disease (such as, but not limited to, undesired vascular smooth muscle proliferation, atherosclerosis, coronary vascular endothelial dysfunction, and/or coronary artery disease), and/or multiple sclerosis.

Abstract: The invention includes a method of preventing or treating metastasis in a subject diagnosed with prostate cancer. In certain embodiments, the metastasis comprises bone cancer. In other embodiments, the subject suffers from castration-resistant prostate cancer.

Abstract: The invention provides methods of treating bone cancer, particularly metastatic bone cancer, by administering an IGF-IR antagonist and/or a PDGFR? antagonist. The invention also provides antibodies that bind to human PDGFR? and neutralize activation of the receptor. The invention further provides a methods for neutralizing activation of PDGFR?, and a methods of treating a mammal with a neoplastic disease using the antibodie alone or in combination with other agents.